Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00348400 · ClinicalTrials.gov registry record · Phase 4

Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost

A Phase 4 study, sponsored by Innovative Medical.

Completed
Registry status
Phase 4
Development phase

NCT00348400: Completed Phase 4 study, sponsored by Innovative Medical.

NCT00348400 is a Phase 4 study that has completed, run by Innovative Medical. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00348400, a Phase 4 study, has completed, sponsored by Innovative Medical.

COMPLETED
Registry status
Phase 4
Development phase

Study Summary

Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

Interventions

  • DRUG Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost

Trial Details

FieldValue
Phase Phase 4
Innovative Medical

44 total trials

What the finished NCT00348400 record still lists

NCT00348400 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 1 intervention - of which Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost is the first listed.

NCT00348400 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00348400 about?

NCT00348400 is a clinical study titled "Brimonidine Purite 0.15% Versus Dorzolamide 2% Used as Adjunctive Therapy to Latanoprost". Evaluate the relative efficacy and tolerability of Alphagan P compared to Trusopt as adjunctive therapy

What is the current status of trial NCT00348400?

This trial is currently completed. It is a Phase 4 study.

What interventions are being tested in trial NCT00348400?

The interventions under investigation include: Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost (DRUG).

Who is sponsoring clinical trial NCT00348400?

This trial is sponsored by Innovative Medical, which has 44 total clinical trials registered on ClinicalTrials.gov.

Source: ClinicalTrials.gov NCT00348400, the US trial registry maintained by the National Library of Medicine. NCT00348400 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.